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Medications in asthmatic children
Background: Prescription patterns of anti-asthma medications in children vary among doctors in dif-
ferent disciplines and settings, and may reflect differences in treatment outcome. The purpose of this study
was to analyze the prescribing patterns of anti-asthma drugs by pediatricians, family physicians and other
practitioners.
Methods: Data for a total of 225,537 anti-asthma prescriptions were collected from the National Health
Insurance Research Database for the period from January 1, 2002 to March 31, 2002. These medications
included inhaled and oral adrenergics, inhaled and oral corticosteroids, xanthine derivatives, and leuko-
triene receptor antagonists prescribed by general pediatricians, family physicians and physicians in other
disciplines.
Results: Oral `2-agonist was the most commonly prescribed drug used as monotherapy, with prescription
rates of 70.4%, 46.9% and 58.0% by pediatricians, family physicians and other physicians, respectively. A
xanthine derivative was the next most commonly prescribed monotherapy. Oral corticosteroid combined
with oral `2-agonist, followed by oral `2-agonist combined with a xanthine derivative were the two most
commonly prescribed dual-agent combined therapies by all three physician categories. The prescription rate
for inhaled corticosteroid monotherapy was 7.8% by pediatricians, 5.6% by family physicians, and 8.0% by
other physicians. The prescription rate for inhaled adrenergic was the highest in family physicians (14.9%),
followed by the other physicians (7.2%), and was lowest in pediatricians (3.1%).
Conclusion: Pediatricians and family physicians appeared to share similar opinions on the medical
management of children with asthma in that both most commonly prescribed oral `2-agonists and xanthine
derivatives, either alone or in combination. Family physicians were least likely to prescribe an inhaled
corticosteroid and most likely to prescribe an inhaled adrenergic agent. [ J Formos Med Assoc 2006;105(4):
277–283]
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Asthma has become more common in both chil-
dren and adults around the world in recent de-
cades.1 The rate of asthma has increased as com-
munities adopt Western lifestyles and become
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urbanized.2 Similar changes in lifestyle and in-
creasing rates of asthma have occurred in Taiwan,
where the prevalence of asthma increased from
5.1% to 9.4% between 1985 and 1997.3,4 In 1989,
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sonal and medical care institutions’ IDs in the da-
tabase were scrambled in compliance with the Per-
sonal Electronic Data Protection Law.
Data collection
Data were collected on all prescriptions for all pa-
tients younger than 16 years old during the period
from January 1, 2002 to March 31, 2002. Prescribed
drugs were classified according to the Anatomical
Therapeutic Chemical (ATC) classification system
to facilitate international comparison. Medications
were grouped into the following six categories:
inhaled adrenergics (i.e. _- and `-adrenoreceptor
agonists, selective `2-adrenoreceptor agonists),
oral `2-agonists, inhaled corticosteroids, xanthine
derivatives, oral corticosteroids, and leukotriene
receptor antagonists.
Patient subgroups
Asthmatic patients were selected based on a
diagnosis (International Classification of Diseases
[ICD], Ninth Revision, Clinical Modification
ICD-9-CM code 493.xx) of asthma as a principal
or secondary condition made at an outpatient visit.
A maximum of three outpatient diagnoses could
be listed.
Three subgroups of patients within the 0–16-
year-old group were studied. The first subgroup
consisted of patients who had visited pediatricians
who were restricted to pediatric practice by the
National Health Insurance system. The second
group consisted of those who had visited family
physicians who were restricted to family medicine
practice by the National Health Insurance system.
The last group of patients had visited other health
care providers who were neither pediatricians nor
family physicians, including other specialists, such
as internal medicine specialists, or ear, nose and
throat specialists.
Statistical analysis
All analyses were performed using SAS version
8.2 for Windows (SAS Institute Inc, Cary, NC,
USA). We used standard methods for analyzing
contingency tables. For 2 × 2 tables, p values were
based on the continuity-adjusted Pearson chi-
a learning program for physicians named the
Global Initiative for Asthma (GINA) program
was begun in an effort to raise awareness among
health care workers and the general public about
the increasing rates of asthma and the need for
standardized asthma care.5 According to GINA
guidelines, several drugs are recommended either
alone or in combination to treat asthma, includ-
ing `2-agonists (oral or inhaled form), cortico-
steroids (oral or inhaled form), xanthine deri-
vatives, and leukotriene receptor antagonists.
It is often assumed that much of the leader-
ship for defining optimal medical care for asthma
emerges from the knowledge, attitudes, beliefs,
and actual practice patterns of medical care
specialists. Due to cultural differences, an ineffi-
cient and poorly functioning referral system, and
comparatively convenient access to health care
provided by the National Health Insurance sys-
tem in Taiwan, asthma care in children is pro-
vided by a wider array of medical practitioners
than is common in the West, including general
pediatricians, family physicians and other phy-
sicians, such as those specializing in internal
medicine. The differences in the quality of care
and care preferences for asthmatic children pro-
vided by pediatricians, family physicians and
other practitioners remain unclear. This study
analyzed the prescribing patterns of anti-asthma
drugs by pediatricians, family physicians and
other practitioners using data obtained from the
National Health Insurance Research Database.
Methods
Data source
The National Health Insurance Research Data-
base served as the data source for this study. The
information in each computerized claim form in-
cluded patients’ personal identification number
(ID), age, gender, prescription dates, medical care
institutions, drugs prescribed (the drug thera-
peutic code can be used to identify the drug dis-
pensed), and the diagnosis relevant for the pre-
scription and medical expense claims. Both per-
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square test. All p values of less than 0.05 indicated
statistical significance.
Results
A total of 225,537 prescriptions were written
during the 3-month study period. Pediatricians
wrote the highest number of prescriptions among
the three categories of health care providers. They
were also least likely to prescribe a single medi-
cation only compared with family physicians and
other care providers, and were most likely to pre-
scribe more than two medications (Table 1).
The frequency distribution of single medica-
tion use by pediatricians, family physicians and
other care providers is shown in Table 2. Oral
`2-agonist was the most frequently prescribed
monotherapy by pediatricians (70.4%), followed
by xanthine derivatives (16.9%), inhaled cortico-
steroids (7.8%), and inhaled adrenergics (3.1%).
Family physicians most frequently prescribed
oral `2-agonist (46.9%), followed by xanthine de-
rivatives (30.1%). The percentage of prescriptions
for inhaled adrenergics by family physicians
was higher than that by pediatricians (14.9% vs.
3.1%; p < 0.05), while the percentage of inhaled
corticosteroids prescribed by family physicians
was lower (7.8% vs. 5.6%; p < 0.05). Among all
other care providers, oral `2-agonist (58.0%) and
xanthine derivatives (23.6%) were the two most
frequently prescribed drugs, followed by inhaled
adrenergics (7.2%) and inhaled corticosteroids
(8.0%). The percentage of outpatient visits with
leukotriene receptor antagonist prescription was
< 2.5% in all care provider groups.
The frequency distribution of combining two
medications in prescriptions by pediatricians,
family physicians and other physicians is shown
in Table 3. Oral `2-agonists combined with a
xanthine derivative was the most common combi-
nation therapy prescribed by pediatricians, family
physicians and other physicians. The second most
commonly prescribed combination by all three
groups was oral corticosteroid combined with
oral `2-agonist. Oral corticosteroid combined with
a xanthine derivative was the third most common-
ly prescribed two-drug combination by family
physicians (14.6%), while inhaled corticosteroid
combined with an oral `2-agonist (7.0%) was the
third most common prescription among pedia-
tricians, and an inhaled adrenergic agent com-
bined with an oral `2-agonist was the third most
common (9.2%) among the other physicians.
Table 1. Anti-asthma medications prescribed by various types of physicians
Number of prescribed medications Pediatricians Family physicians Other physicians
One medication, n (%) 64,211 (34.6) 3405 (45.8) 14,653 (45.2)
Two medications, n (%) 74,026 (39.9) 3260 (43.8) 11,145 (34.4)
> Two medications, n (%) 47,472 (25.6) 0771 (10.4) 06594 (20.4)
Total prescriptions, n 185,709 7436 32,392
Table 2. Frequency distribution of medications prescribed as monotherapy
Pediatricians Family physicians Other physicians
Inhaled adrenergic agent, % 03.1 14.9 07.2
Inhaled corticosteroid, % 07.8 05.6 08.0
Oral `2-agonist, % 70.4 46.9 58.0
Xanthine derivative, % 16.9 30.1 23.6
Oral corticosteroid, % 00.0 00.8 01.2
Leukotriene receptor agonist, % 01.8 01.7 02.0
Total prescriptions, n 64,211 3405 14,653
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The frequency distribution of prescriptions
combining three or more medications by pedia-
tricians, family physicians and other physicians
are shown in Table 4. Combination of an oral
corticosteroid, oral `2-agonist and a xanthine de-
rivative was the most common combination of
three or more drugs prescribed by all three phy-
sician groups. The second most common combi-
nation of three or more drugs varied among the
three types of physicians, with inhaled adrener-
gic agent plus oral corticosteroid plus oral `2-
agonist plus a xanthine derivative most common-
ly prescribed by pediatricians (13.5%), and in-
haled adrenergic agent plus oral corticosteroid
plus oral `2-agonist most commonly prescribed
by family physicians (8.8%) and other care pro-
viders (21.8%). Family physicians who used a
combination of three or more drugs showed a
marked preference for the combination of oral cor-
ticosteroid plus oral `2-agonist plus a xanthine
derivative.
Discussion
This study found that oral `2-agonist was the
most commonly prescribed monotherapy by pedi-
atricians, family physicians and other types of
physicians treating children with asthma in Taiwan.
Previous studies in other countries found similar
results. Grant et al reported that oral `2-agonists
were the most commonly prescribed type of medi-
cation, with 80.8% of primary care physicians
reporting that they were most likely to prescribe
them in patients < 5 years old with moderate per-
sistent asthma.6 A retrospective analysis of 28,000
asthmatic patients treated in five managed care
settings by Buchner et al found that the use of bron-
chodilators without inhaled anti-inflammatory
therapy was the dominant pattern of pharmaco-
logic therapy.7 As in this study, they also found
that oral `2-agonist was the most commonly pre-
scribed therapy in all regimens. Oral forms of
therapy are easier for patients to use and do not
Table 3. Frequency distribution of prescriptions of combined therapies using two medications
Pediatricians Family physicians Other physicians
OBA+XAN 40.6% OBA+XAN 48.4% OBA+XAN 34.5%
OCS+OBA 36.4% OCS+OBA 28.0% OCS+OBA 29.3%
ICS+OBA 07.0% OCS+XAN 14.6% IBA+OBA 09.2%
IBA+OBA 05.9% IBA+XAN 01.7% OCS+XAN 07.5%
OCS+XAN 03.3% IBA+ICS 01.6% ICS+OBA 04.8%
Other 06.8% Other 05.7% Other 14.7%
Total prescriptions, n 74,026 3260 11,145
IBA = inhaled adrenergic agent; ICS = inhaled corticosteroid; OBA = oral `2-agonist; OCS = oral corticosteroid; XAN = xanthine
derivative; Other = remaining possible two-drug combinations.
Table 4. Frequency distribution of prescriptions of combined therapies using three or more medications
Pediatricians Family physicians Other physicians
OCS+OBA+XAN 33.3% OCS+OBA+XAN 54.7% OCS+OBA+XAN 23.0%
IBA+OCS+OBA+XAN 13.5% IBA+OCS+OBA 08.8% IBA+OCS+OBA 21.8%
ICS+OCS+OBA 12.2% IBA+OCS+OBA+XAN 06.7% IBA+OCS+OBA+XAN 11.5%
IBA+OCS+OBA 12.1% IBA+OBA+XAN 05.6% IBA+OBA+XAN 08.7%
IBA+OBA+XAN 08.8% ICS+OBA+XAN 05.6% IBA+ICS+OCS+OBA 06.2%
Other 20.3% Other 18.6% Other 28.8%
Total prescriptions, n 47,472 771 6594
IBA = inhaled adrenergic agent; ICS = inhaled corticosteroid; OBA = oral `2-agonist; OCS = oral corticosteroid; XAN = xanthine
derivative; Other = remaining possible three-drug combinations.
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require physicians to spend additional time as
would be required to demonstrate how to use in-
haled preparations. This convenience may be one
of the factors responsible for the high rate of pre-
scription of oral `2-agonists.
According to GINA guidelines, xanthine deriv-
atives serve as an adjunctive therapy that can be
added to regimens of patients whose asthma is not
completely controlled by inhaled `-agonist and in-
haled corticosteroids. This study found that xan-
thine derivatives were widely used in the treatment
of bronchial asthma, being prescribed in 22.7%
of patients. In a population-based longitudinal
analysis conducted between 1984 and 1993, Good-
man et al measured trends in all pediatric uses of
medications for asthma.8 Oral theophylline use
declined 10-fold to only 0.25% of prescriptions in
the pediatric population during the study period.
The relative efficacy of theophylline therapy has
been established for several decades.9–11 However,
because of its narrow therapeutic range, the dos-
age must be individualized in order to optimize
the treatment based on the measurement of se-
rum theophylline concentration. If theophylline
therapy is to be used safely, clinicians must be
quite familiar with numerous factors that alter
clearance of this drug, and they must be prepared
to use an appropriate dosage and monitor serum
concentrations.12
In this study, the prescription rates for leuko-
triene receptor antagonists were very low. Because
the marketing of leukotriene receptor antagonists
in Taiwan only began in the winter of 2001, i.e.
just before the beginning of the study period,
these low rates may be partly attributable to lack
of awareness of this new treatment option by many
physicians.
Among the two-drug combination therapies,
an oral `2-agonist combined with a xanthine
derivative, and oral corticosteroid combined with
an oral `2-agonist were the most frequently pre-
scribed by all three categories of physicians. These
results are in agreement with a study by Eggleston
et al.13 Their data, obtained by parental question-
naire, revealed that adrenergic agonists were pre-
scribed in 221 of 396 (56%) asthmatic children,
either as monotherapy (34%) or in combination
with theophylline (22%). Lozano et al found that
the most common asthma medication regimens
used by children with asthma in the USA were oral
`2-agonist (15.4%), `2-agonist plus theophyl-
line (10.4%), theophylline (6.1%) and `2-agonist
plus corticosteroid (2.7%).14 Thus, oral `2-agonist,
theophylline and oral corticosteroid are the most
commonly prescribed drugs in both Taiwan and
abroad, although the percentage of prescriptions
involving each of these agents was higher in this
study than in the previous studies.
The use of oral corticosteroid monotherapy was
very low in this study. Oral corticosteroid, how-
ever, was commonly included in combined thera-
py with two or more drugs. The use of oral cortico-
steroid combined with an oral `2-agonist was
the second most common dual-drug therapy,
ranging from 28.0% to 36.4% among the differ-
ent groups of physicians treating asthmatic
children. Oral corticosteroid was included in all
of the three most commonly prescribed combina-
tion regimens involving three or more agents by
all three physician groups. Thus, oral cortico-
steroid plays an especially large role in combina-
tion therapies for asthma in children. According
to GINA guidelines, oral corticosteroid should be
prescribed for severe persistent symptoms or as
a burst in patients with acute asthma attack.
Whether the use of oral corticosteroid in this
study’s patients represents excessive treatment on
a regular basis that is outside of the recommended
guidelines remains to be clarified. Our data may
suggest the need for more extensive trials of in-
haled anti-inflammatory therapy prior to the in-
troduction of oral corticosteroid.
Based, in part, on evidence that intervention
will prevent or reduce airway damage and result
in beneficial long-term effects on asthma mor-
bidity, GINA guidelines emphasize the use of in-
haled anti-inflammatory agents, particularly corti-
costeroid. In this study, family physicians demon-
strated the lowest prescription rate of inhaled cor-
ticosteroid (5.6%). This rate is lower than in studies
from other countries. Halterman et al studied a
total of 1025 American children with physician-
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diagnosed asthma, and found that only 26% of
those with moderate to severe asthma had taken
a maintenance medication.15 In Germany, Beim-
fohr et al found that 16.3% of asthmatic children
had used inhaled corticosteroid.16 In Great Britain,
Warner found that 39% of asthmatic children were
prescribed inhaled corticosteroid.17 In Taiwan,
many parents are concerned about the side ef-
fects of inhaled corticosteroids that are to be used
as controller medications for at least 3 months.
Such concerns may affect a physician’s intention
to prescribe inhaled corticosteroid. In addition,
the quality of the interaction between physicians,
parents and children affects treatment efficiency.
Another study found that significantly fewer
children aged 3–5 years old received any control-
ler medication compared to older children (p <
0.001).18 Further analysis of data for the different
age groups in this study revealed that family
physicians were less likely to prescribe inhaled cor-
ticosteroid than pediatricians (2.3% vs. 4.8%) in
children younger than 5 years.
In this study, family physicians had the high-
est prescription rate for inhaled adrenergics
(14.9%). In patients younger than 5 years old,
the percentage of outpatient prescriptions of in-
haled adrenergic was higher than expected at
7.6%. A previous population-based study in
Taiwan found that inhaled adrenergics were pre-
scribed in 10.7% of children.19 As a symptom re-
liever, an inhaled adrenergic is the most effective
of the bronchodilators, especially in terms of its
`-agonist effect.20 Because of their quick onset
and short duration of action, inhaled `-agonists
are apt to be improperly used and may be a
risk factor for asthma death.21,22 GINA guidelines
and the findings of some previous studies23,24
remind us that frequent preventive treatment
with `-adrenergic agents is still an indication for
concomitant therapy with anti-inflammatory
drugs.
Recent studies indicated that the addition of
`-agonist to the regimen of symptomatic patients
with a low to moderate dosage of inhaled steroid
improved lung function and increased the number
of symptom-free days and nights.25,26 It was also
recommended that inhaled corticosteroid plus
long-acting inhaled `2-agonist be prescribed for
patients with persistent asthma during the moder-
ate to severe stages of the disease. This study
found that combined treatment using both in-
haled corticosteroid and `-adrenergic agents
was prescribed at < 1% of outpatient visits in all
three physician groups. This may be due to the
lack of familiarity with newer treatment concepts
or underestimation of asthma severity in pediatric
patients.
Several limitations of this study should be
noted. This study was a retrospective analysis of
claims data as opposed to prospective referral
data. Assessment of illness severity was not pos-
sible because of the exclusive use of computerized
prescription drug data on dispensed medications
and physicians’ diagnosis ICD codes. Thus, pa-
tients could not be classified into the four severity
groups to evaluate whether the prescribing pat-
terns followed GINA guidelines. In addition, the
findings reflect how asthma care was provided
at only one outpatient visit for each patient. How
prescription patterns change over the course of
illness in patients remains unclear. Determination
of the extent of the pediatric asthma care burden
assumed by pediatricians and family physicians in
Taiwan also remains unclear and would require
longitudinal follow-up study.
In conclusion, this study found that oral `2-
agonist and xanthine derivatives were the most
commonly dispensed asthma monotherapies in
pediatric asthma in Taiwan, regardless of the type
of practitioner seen at the clinic. Oral corticoster-
oid combined with oral `2-agonist, and oral `2-
agonist combined with a xanthine derivative were
the two most common dual-drug therapies. The
prescription patterns of pediatricians and family
physicians generally suggested that they shared
similar opinions on the medical management of
children with asthma, except for the use of anti-
inflammatory controller drugs, for which the pre-
scription rate of inhaled corticosteroid was higher
among pediatricians than among family physi-
cians (7.8% vs. 5.6%). With regard to a symptom
reliever, however, the prescription rate of inhaled
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adrenergics by pediatricians was far lower than by
family physicians (3.1% vs. 14.9%).
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